glycyrrhizin
gl
known
variou
immunomodul
activ
long
use
clinic
antiallerg
antihepat
agent
potenc
gl
lung
inflammatori
diseas
expect
effect
gl
lung
poorli
understood
lung
fibroblast
known
potent
produc
inflammatori
chemokin
eotaxin
neutrophil
eosinophil
strongli
attract
inflamm
therefor
studi
effect
gl
product
chemokin
use
human
fetal
lung
fibroblast
cell
line
stimul
tnfa
moreov
examin
structureact
relationship
gl
explor
benefici
compound
hgl
inhibit
dosedepend
inhibit
eotaxin
slightli
hglycyrrhet
acid
ga
inhibit
inhibit
eotaxin
effect
hglycyrrhet
acid
monoglucuronid
mga
resembl
hgl
weaker
oxi
acid
oxi
acid
heterogl
exhibit
inhibitori
activ
signific
cytotox
oxi
acid
homogl
cytotox
activ
mild
like
hgl
oxi
oxi
show
potent
see
front
matter
itori
effect
concentr
lower
hgl
signific
cytotox
result
suggest
glrelat
compound
effect
reduc
chemokin
product
glmodifi
compound
includ
appear
benefici
view
inhibitori
capac
less
cytotox
pulmonari
fibroblast
recogn
activ
particip
inflammatori
process
lung
play
special
role
recruit
regul
immun
cell
infiltr
interstiti
space
regulatori
mechan
lung
fibroblast
gener
mani
kind
chemokin
cytokin
includ
eotaxin
rant
gmcsf
upon
activ
inflammatori
stimul
one
major
chemokin
neutrophil
chemotact
activ
produc
varieti
cell
includ
lung
fibroblast
activ
variou
stimul
hand
eotaxin
origin
isol
predomin
eosinophil
chemoattract
lung
lavag
fluid
sensit
guinea
pig
allerg
exposur
clone
kitaura
et
al
eotaxin
produc
sever
type
cell
includ
lung
dermal
fibroblast
lung
bronchial
epitheli
cell
product
eotaxin
induc
suppress
ifng
recogn
eotaxin
respons
infiltr
eosinophil
allerg
inflammatori
site
glycyrrhizin
gl
triterpen
glycosid
extract
licoric
root
glycyrrhiza
glabra
consist
glycyrrhet
acid
ga
two
molecul
glucuron
acid
posit
see
fig
past
decad
gl
prepar
strongerneo
minophagen
c
snmc
extens
use
treat
chronic
hepat
japan
safeti
efficaci
snmc
establish
snmc
clinic
trial
europ
patient
chronic
hepat
c
far
gl
demonstr
varieti
activ
product
sever
cytokin
name
ifng
augment
nk
cellnkt
cell
activ
also
gl
administr
induc
antiinflammatori
cytoprotect
effect
vivo
antivir
effect
vitro
pharmacolog
effect
gl
relat
compound
demonstr
earli
sever
acut
respiratori
syndrom
sar
rage
sever
countri
event
shook
world
surprisingli
promptli
report
gl
effect
sarsassoci
coronaviru
subsequ
paper
report
elev
plasma
inflammatori
cytokin
chemokin
observ
sar
patient
take
report
consider
presum
gl
may
act
product
chemokin
lung
howev
effect
gl
chemokin
product
lung
constitu
cell
remain
identifi
studi
investig
inhibitori
effect
gl
relat
compound
chemokin
product
human
lung
fibroblast
known
good
produc
chemokin
focus
eotaxin
sinc
chemokin
recruit
polymorphonuclear
cell
neutrophil
eosinophil
lung
inflamm
also
investig
structureact
relationship
gl
deriv
glrelat
compound
use
except
hdglucopyranuronosylhdglucopyranuronosyl
oxi
oxi
alreadi
report
elsewher
sinc
latter
two
compound
report
elsewher
herein
briefli
describ
chemic
prepar
oxi
heterogl
treat
hydrogen
chlorid
methanol
room
temperatur
give
dimethyl
ester
acetyl
afford
dimethyl
ester
pentaacet
yield
treat
ethyl
chloroform
triethylamin
follow
sodium
borohydrid
afford
yield
follow
salt
format
compound
dissolv
etoh
contain
serum
free
medium
mgml
dilut
fetal
bovin
serum
fb
contain
medium
disodium
salt
ammonium
salt
hglycyrrhet
acid
monoglucuronid
potassium
salt
dissolv
dmso
dilut
fb
contain
medium
final
concentr
etoh
dmso
less
except
high
concentr
latter
three
compound
concentr
etoh
dmso
use
compar
control
human
recombin
tnfa
kindli
provid
dainippon
pharmaceut
suitashi
osaka
japan
human
recombin
rabbit
polyclon
antihuman
eotaxin
antibodi
purchas
peprotech
ec
london
uk
horseradish
peroxidaseconjug
swine
antirabbit
antibodi
obtain
dako
denmark
human
fetal
lung
fibroblast
normal
embryon
lung
diploid
origin
atcc
purchas
riken
cell
bank
saitama
japan
cell
cultur
confluenc
ham
gibco
grand
island
ny
supplement
heatinactiv
fb
unitsml
penicillin
g
agml
streptomycin
humidifi
co
air
collagenco
cultur
dish
iwaki
chiba
japan
cell
seed
densiti
cell
per
well
collagenco
plate
incub
overnight
adher
remov
cultur
media
variou
concentr
compound
dilut
fb
contain
medium
ad
cell
stimul
tnfa
tnfa
plu
incub
sinc
publish
report
indic
costimul
tnfa
caus
synergist
upregul
eotaxin
product
mrna
express
adopt
stimul
condit
eotaxin
measur
time
cours
experi
cell
incub
tnfa
tnfa
plu
h
experi
cell
incub
ngml
tnfa
h
ngml
tnfa
plu
uml
h
eotaxin
indic
time
supernan
harvest
store
elisa
lactat
dehydrogenas
ldh
assay
experi
control
cell
incub
compound
vehicl
period
time
experiment
cell
concentr
eotaxin
cultur
medium
measur
elisa
method
describ
elsewher
coat
ab
monoclon
ab
agml
monoclon
antieotaxin
ab
agml
ab
rabbit
polyclon
ab
agml
antieotaxin
ab
agml
use
sampl
assay
least
duplic
system
crossreact
member
chemokin
famili
averag
concentr
eotaxin
detect
sampl
treat
stimul
alon
ngml
respect
cytotox
test
compound
evalu
ldh
assay
releas
ldh
supernan
determin
describ
ldhcytotox
test
kit
wako
osaka
japan
sinc
ldh
assay
well
correl
mtt
assay
shown
sole
data
ldh
assay
studi
mrna
eotaxin
mrna
analyz
rtpcr
cell
incub
compound
total
rna
extract
adher
cell
use
rneasi
mini
kit
qiagen
hilden
germani
rna
revers
transcrib
accord
manufactur
protocol
takara
bio
shiga
japan
use
oligo
dt
primer
ag
total
rna
firststrand
cdna
synthesi
pcr
perform
anneal
temperatur
amplif
cycl
amplif
cycl
eotaxin
amplif
cycl
dehydrogenas
gapdh
use
housekeep
gene
pcr
product
appli
agaros
gel
electrophores
tri
borateedta
human
amplifi
primer
sens
antisens
humaneotaxin
amplifi
primer
v
sens
antisens
humangapdh
amplifi
primer
sens
antisens
rtpcr
two
dose
set
inhibitori
concentr
ic
valu
calcul
elisa
data
mrna
level
eotaxin
cell
treat
select
concentr
compound
compar
result
express
mean
valuesfsd
three
experi
statist
analysi
perform
use
student
ttest
p
valu
less
consid
signific
identifi
inhibitori
effect
glycyrrhizin
deriv
chemokin
product
human
lung
fibroblast
focus
two
main
chemokin
eotaxin
glycyrrhizinrel
compound
tent
classifi
five
group
isom
conform
rel
structur
fig
investig
effect
compound
eotaxin
product
mrna
express
sinc
signific
eotaxin
product
induc
compound
alon
data
shown
effect
tnfa
tnfa
plu
chemokin
product
evalu
effect
belong
group
compound
chemokin
product
mrna
express
cytotox
shown
fig
compound
exhibit
similar
inhibitori
effect
product
gradual
dosedepend
curv
signific
inhibit
observ
agml
product
reduc
agml
cytotox
slightli
stronger
fig
cc
agml
vs
agml
tabl
indic
signific
effect
mrna
express
inhibit
mrna
express
moder
agml
fig
hand
effect
compound
eotaxin
product
mrna
express
rather
differ
inhibitori
effect
eotaxin
product
lower
concentr
ic
agml
cytotox
compound
mitig
presenc
fig
compar
tnfa
alon
fig
action
compound
eotaxin
mrna
express
basic
parallel
elisa
data
ie
inhibit
mrna
express
slightli
agml
inhibit
dose
fig
effect
aglycon
form
bgl
next
examin
group
aglycon
compound
inhibit
rather
increas
product
less
agml
fig
result
rtpcr
basic
correspond
result
elisa
agml
fig
concentr
agml
cytotox
fig
c
test
higher
dose
note
compound
affect
eotaxin
product
two
phase
enhanc
low
dose
agml
increas
eotaxin
product
inhibit
agml
inhibitori
effect
stronger
fig
addit
effect
group
monoglucuronid
form
hgl
test
shown
fig
b
mark
inhibit
eotaxin
product
exhibit
monoglucuronid
form
five
compound
classifi
group
form
partli
common
structur
carbonyl
group
posit
reduc
inhibitori
effect
homogl
heterogl
group
shown
fig
heterogl
drastic
decreas
product
around
agml
approxim
cytotox
observ
agml
ngml
h
tnfa
plu
uml
eotaxin
supernan
collect
eotaxin
accumul
measur
elisa
describ
materi
method
point
repres
meanfsd
three
independ
experi
compar
effect
tnfa
tnfa
plu
ldh
releas
cell
cours
experi
use
measur
cytotox
ldh
activ
supernan
determin
use
ldhcytotox
test
kit
accord
manufacturert
protocol
mean
ldh
releas
three
independ
experi
shown
cytotox
index
sd
less
total
rna
ag
extract
tnfatreat
cell
tnfa
plu
cell
eotaxin
use
rtpcr
specif
human
eotaxin
primer
gapdh
prime
intern
control
ratio
chemokin
mrna
express
rel
gapdh
express
calcul
densitometr
rtpcr
photo
compound
fig
morpholog
chang
cell
detect
concentr
name
fibrou
shape
cell
chang
round
shape
data
shown
action
homogl
similar
hgl
homogl
moder
inhibit
product
like
hgl
shown
fig
contrast
heterogl
homogl
show
notabl
cytotox
even
high
concentr
fig
result
rtpcr
three
compound
correspond
elisa
data
fig
hand
three
compound
decreas
eotaxin
product
less
agml
dosedepend
manner
fig
homogl
rather
weaker
two
compound
inhibitori
effect
eotaxin
mrna
express
evid
fig
final
examin
effect
group
compound
compound
reduc
form
heterogl
homogl
modifi
carboxyl
group
effect
inhibit
eotaxin
product
hgl
heterogl
homogl
compound
inhibit
chemokin
releas
lower
concentr
appar
cytotox
observ
fig
c
eotaxin
mrna
express
inhibit
dosedepend
result
correspond
elisa
data
fig
inhibitori
concentr
cytotox
concentr
glycyrrhizin
relat
compound
calcul
shown
tabl
take
concentr
rang
ic
cc
consider
assum
valuabl
inhib
ition
eotaxin
product
cell
view
safeti
efficaci
sever
report
indic
gl
immunomodulatori
capac
regul
type
cytokin
addit
sasaki
et
al
report
gl
induc
gener
ccchemokin
rant
peripher
blood
mononuclear
cell
hivinfect
patient
studi
focus
modulatori
effect
gl
deriv
eotaxin
product
human
lung
fibroblast
sinc
glucuron
acid
posit
gl
deriv
seem
import
activ
modul
posit
modifi
part
first
remov
glucuron
acid
chang
configur
hydrogen
atom
gl
view
structureact
relationship
among
gl
ga
mga
glucuron
acid
differ
effect
eotaxin
gener
hgl
inhibit
product
gradual
dose
depend
manner
show
inhibitori
effect
eotaxin
product
howev
mrna
level
well
correl
amount
chemokin
therefor
hgl
may
regul
chemokin
product
also
posttranscript
level
like
protein
secret
degrad
experi
need
explor
detail
one
molecul
glucuron
acid
remov
gl
mga
show
signific
differ
eotaxin
product
cytotox
increas
cc
agml
compar
agml
hgl
moreov
two
molecul
glucuron
acid
remov
gl
ga
indic
rather
differ
action
eotaxin
product
ga
show
inhibitori
action
product
agml
ga
show
inhibitori
effect
eotaxin
product
less
agml
increas
cytotox
agml
result
eotaxin
mrna
express
ag
ml
necessarili
correspond
result
elisa
reason
remain
unclear
concentr
seem
close
cytotox
concentr
effect
ga
protein
level
mrna
level
might
unstabl
altern
time
eotaxin
product
start
later
kinet
differ
may
reflect
differ
effect
ga
stereospecif
posit
great
differ
except
eotaxin
product
much
stronger
effect
eotaxin
product
second
examin
structureact
relationship
compound
group
compar
effect
homogl
heterogl
modifi
heterogl
indic
strong
inhibit
agml
cytotox
aros
simultan
heterogl
previous
report
com
pound
inhibitori
action
hiv
herp
simplex
viru
replic
therefor
pharmacolog
potenc
heterogl
expect
found
rang
efficaci
toxic
narrow
demonstr
effect
homogl
eotaxin
product
weaker
heterogl
less
cytotox
effect
homogl
eotaxin
product
mrna
level
correl
protein
level
homogl
also
may
modul
eotaxin
product
porttranscript
level
well
gl
moreov
group
modifi
compound
heterogl
homogl
posit
compound
show
moder
inhibitori
activ
eotaxin
express
ic
eotaxin
lower
gl
cytotox
less
heterogl
term
ic
ic
agml
ic
eotaxin
agml
superior
homogl
result
suggest
reduct
carboxyl
group
may
augment
inhibitori
activ
without
chang
cytotox
taken
collect
modif
gl
posit
may
augment
activ
gl
gl
use
wide
effect
treatment
chronic
hepat
furthermor
gl
describ
antivir
agent
mani
kind
virus
includ
herp
simplex
viru
type
hiv
human
cytomegaloviru
cmv
influenza
viru
sarsassoci
coronaviru
etc
murayama
et
al
demonstr
enhanc
human
cmv
replic
human
lung
fibroblast
also
elev
observ
sar
patient
thu
seem
close
connect
viral
infect
product
lung
addit
known
signific
attract
inflammatori
cell
chronic
obstruct
pulmonari
diseas
copd
therefor
result
studi
gl
relat
compound
reduc
gener
human
lung
fibroblast
explain
activ
antiinflammatori
drug
lung
diseas
eotaxin
thought
potent
eosinophil
chemotact
factor
recruit
eosinophil
airway
allerg
stimul
notion
support
vivo
experi
moreov
correl
eotaxin
eosinophil
accumul
bronchoalveolar
lavag
asthmat
patient
identifi
studi
demonstr
gl
deriv
inhibitori
capac
eotaxin
product
caus
tnfa
plu
stimul
lung
fibroblast
result
would
impli
gl
deriv
could
use
antiallerg
antiinflammatori
agent
lung
eosinophil
diseas
like
asthma
gl
also
abil
enhanc
cytokin
ifng
modul
cytokin
enhanc
reduct
cell
gener
eotaxin
induc
suppress
ifng
glrelat
compound
may
improv
allerg
inflammatori
lung
diseas
inhibit
proinflammatori
chemokin
product
also
shift
axi
although
gl
need
high
dose
ie
mgml
inhibit
eotaxin
product
demonstr
glrelat
compound
especi
effect
much
lower
dose
less
agml
thu
assum
compound
benefici
perspect
inhibitori
concentr
cytotox
summari
present
studi
show
inhibitori
effect
gl
relat
compound
eotaxin
product
human
lung
fibroblast
notabl
glmodifi
compound
presum
good
candid
inhibitori
activ
eotaxin
product
